CAS 1802929-43-6

Formula: C26H30Cl2N6O4

InChI: InChI=1S/C26H30Cl2N6O4/c1-5-20(35)33-11-9-32(10-12-33)7-6-8-34-24-16(15-30-26(29-2)31-24)13-17(25(34)36)21-22(27)18(37-3)14-19(38-4)23(21)28/h5,13-15H,1,6-12H2,2-4H3,(H,29,30,31)

InChI key: PUIXMSRTTHLNKI-UHFFFAOYSA-N

SMILES: CNC1=NC=C2C=C(C(=O)N(C2=N1)CCCN3CCN(CC3)C(=O)C=C)C4=C(C(=CC(=C4Cl)OC)OC)Cl

PRN1371

CAS: 1802929-43-6

PRN1371

Formula: C₂₆H₃₀Cl₂N₆O₄

Purezza: 98.5%

Peso molecolare: 561.46

Ref: 54-BUP04899

PRN1371

CAS: 1802929-43-6

PRN1371 is a specific and potent FGFR1-4 and CSF1R inhibitor (IC50s: 0.6/1.3/4.1/19.3/8.1 nM for FGFR1/2/3/4 and CSF1R).

Formula: C₂₆H₃₀Cl₂N₆O₄

Purezza: 98.65%

Colore e forma: Solid

Peso molecolare: 561.46

Ref: TM-TQ0015

PRN1371

CAS: 1802929-43-6

PRN1371 is a novel, small molecule compound that inhibits the activity of cyclin-dependent kinases 4 and 6 (CDK4/6). It is a selective inhibitor of CDK4/6 that has been shown to inhibit tumor growth and metastasis in experimental models. PRN1371 has demonstrated an ability to inhibit tumor growth by targeting the CDK4/6 pathway, which is important for cell cycle progression. This agent also interacts with hydrogen bonds, which may contribute to its selectivity. PRN1371 binds to the protein target with high affinity and specificity.
PRN1371 is currently being studied in phase II clinical trials for pediatric patients with bladder cancer.

Formula: C₂₆H₃₀Cl₂N₆O₄

Purezza: Min. 98 Area-%

Colore e forma: Powder

Peso molecolare: 561.46 g/mol

Ref: 3D-BP179867

PRN1371

CAS: 1802929-43-6

8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one

Formula: C₂₆H₃₀Cl₂N₆O₄

Purezza: 99%

Peso molecolare: 561.46

Ref: IN-DG767788

6-(2,6-Dichloro-3,5-dimethoxyphenyl)-2-(methylamino)-8-[3-[4-(1-oxo-2-propen-1-yl)-1-piperazinyl]propyl]pyrido[2,3-d]pyrimidin-7(8H)-one

CAS: 1802929-43-6

Formula: C₂₆H₃₀Cl₂N₆O₄

Purezza: 98%

Colore e forma: Solid

Peso molecolare: 561.4602

Ref: IN-DA01DH0S